Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:L-lysine
go back to main search page
Accession:CHEBI:18019 term browser browse the term
Definition:An L-alpha-amino acid; the L-isomer of lysine.
Synonyms:related_synonym: (2S)-2,6-diaminohexanoic acid;   (S)-2,6-diaminohexanoic acid;   (S)-alpha,epsilon-diaminocaproic acid;   (S)-lysine;   6-ammonio-L-norleucine;   Formula=C6H14N2O2;   InChI=1S/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1;   InChIKey=KDXKERNSBIXSRK-YFKPBYRVSA-N;   K;   L-2,6-Diaminocaproic acid;   L-Lysin;   LYSINE;   Lys;   Lysine acid;   SMILES=NCCCC[C@H](N)C(O)=O;   lysina;   lysinum
 alt_id: CHEBI:13135;   CHEBI:21351;   CHEBI:43950;   CHEBI:6264
 xref: Beilstein:1722531;   CAS:56-87-1;   DrugBank:DB00123;   Drug_Central:1622;   ECMDB:ECMDB00182;   Gmelin:364182;   HMDB:HMDB0000182;   KEGG:C00047;   KEGG:D02304;   KNApSAcK:C00001378
 xref_mesh: MESH:D008239
 xref: MetaCyc:LYS;   PMID:10930630;   PMID:16901854;   PMID:17051348;   PMID:17979222;   PMID:22019452;   PMID:22064742;   PMID:22575419;   PMID:22735334;   PMID:23167968;   PMID:23325920;   PMID:23722415;   PMID:24064214;   PMID:24831709;   PMID:25108762;   PMID:8070089;   PMID:8587651;   Reaxys:1722531;   Wikipedia:Lysine;   YMDB:YMDB00330
 cyclic_relationship: is_conjugate_acid_of CHEBI:32550;   is_conjugate_base_of CHEBI:32551;   is_enantiomer_of CHEBI:16855;   is_tautomer_of CHEBI:133538;   is_tautomer_of CHEBI:194466



show annotations for term's descendants           Sort by:
L-lysine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egf epidermal growth factor multiple interactions EXP [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] CTD PMID:22689575 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
JBrowse link
goralatide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme increases expression
decreases expression
multiple interactions
ISO goralatide results in increased expression of ACE mRNA
goralatide results in decreased expression of ACE mRNA
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]
CTD PMID:20096676 PMID:33007385 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ace2 angiotensin converting enzyme 2 multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] CTD PMID:33007385 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
CTD PMID:31181250 PMID:33007385 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Agt angiotensinogen multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]
CTD PMID:31181250 PMID:33007385 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Agtr1a angiotensin II receptor, type 1a multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] CTD PMID:33007385 NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
JBrowse link
G Bdkrb1 bradykinin receptor B1 affects abundance
multiple interactions
ISO BDKRB1 protein affects the abundance of goralatide
[BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide
CTD PMID:20096676 NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] CTD PMID:33007385 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] CTD PMID:33007385 NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
JBrowse link
G Gli1 GLI family zinc finger 1 multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]
CTD PMID:31181250 NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
JBrowse link
G Gli2 GLI family zinc finger 2 multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]
CTD PMID:31181250 NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
JBrowse link
G Gli3 GLI family zinc finger 3 multiple interactions EXP
ISO
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]
CTD PMID:31181250 NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
JBrowse link
G Mas1 MAS1 proto-oncogene, G protein-coupled receptor multiple interactions ISO ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] CTD PMID:33007385 NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
JBrowse link
G Ptch1 patched 1 multiple interactions EXP
ISO
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]
CTD PMID:31181250 NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
JBrowse link
G Shh sonic hedgehog signaling molecule multiple interactions ISO
EXP
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]
CTD PMID:31181250 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
JBrowse link
G Smo smoothened, frizzled class receptor multiple interactions EXP
ISO
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein]
CTD PMID:31181250 NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
JBrowse link
G Vim vimentin multiple interactions ISO goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] CTD PMID:33007385 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
JBrowse link
L-homoarginine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Slco4c1 solute carrier organic anion transporter family, member 4C1 increases export ISO SLCO4C1 protein results in increased export of Homoarginine CTD PMID:30865704 NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715
JBrowse link
lisinopril dihydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity ISO Lisinopril analog results in decreased activity of ACE protein CTD PMID:22200082 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Ace2 angiotensin converting enzyme 2 increases expression
multiple interactions
increases activity
EXP
ISO
Lisinopril results in increased expression of ACE2 mRNA
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]
Lisinopril results in increased activity of ACE2 protein
CTD PMID:15897343 PMID:16221218 PMID:27649628 NCBI chr  X:30,293,597...30,340,961
Ensembl chr  X:30,293,589...30,340,977
JBrowse link
G Ache acetylcholinesterase multiple interactions ISO
EXP
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]
CTD PMID:23060470 PMID:31710167 NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
JBrowse link
G Agt angiotensinogen decreases expression
increases expression
affects response to substance
increases secretion
decreases secretion
multiple interactions
affects metabolic processing
ISO
EXP
Lisinopril results in decreased expression of AGT protein
Lisinopril results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased secretion of AGT protein alternative form
Lisinopril results in decreased secretion of AGT protein
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
Lisinopril affects the metabolism of AGT protein
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
CTD PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More... NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression ISO Lisinopril results in decreased expression of BCL2 CTD PMID:10075388 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Cd2ap CD2-associated protein multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] CTD PMID:16636307 NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199
JBrowse link
G Edn1 endothelin 1 decreases secretion ISO Lisinopril results in decreased secretion of EDN1 protein CTD PMID:19079593 NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
JBrowse link
G Gh1 growth hormone 1 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:19225054 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
JBrowse link
G Hpse heparanase multiple interactions EXP [Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] CTD PMID:19429930 NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Lisinopril results in increased expression of IGFBP1 protein CTD PMID:9663927 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] CTD PMID:20051877 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] CTD PMID:23060470 NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nphs2 NPHS2 stomatin family member, podocin multiple interactions EXP Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] CTD PMID:16636307 NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
JBrowse link
G Nppa natriuretic peptide A decreases expression ISO Lisinopril results in decreased expression of NPPA protein CTD PMID:8393685 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
JBrowse link
G Ren renin increases expression
multiple interactions
ISO
EXP
Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA
CTD PMID:2550029 PMID:8915971 PMID:16221218 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
JBrowse link
G RT1-M3-1 RT1 class Ib, locus M3, gene 1 affects expression ISO Lisinopril affects the expression of HLA-G mRNA CTD PMID:25811541 NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
JBrowse link
G Spmip11 sperm microtubule inner protein 11 multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] CTD PMID:16636307 PMID:19293598 NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 multiple interactions EXP [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] CTD PMID:20051877 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] CTD PMID:19293598 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link
royal jelly term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein] CTD PMID:34227456 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO
EXP
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA]
royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]
CTD PMID:30896085 PMID:34227456 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein] CTD PMID:34227456 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
JBrowse link
G Casp3 caspase 3 multiple interactions ISO
EXP
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]
CTD PMID:30896085 PMID:34227456 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp6 caspase 6 multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein] CTD PMID:34227456 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
JBrowse link
G Casp9 caspase 9 multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein] CTD PMID:34227456 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cat catalase multiple interactions EXP
ISO
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]
CTD PMID:20369241 PMID:30896085 PMID:34227456 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA] CTD PMID:35099105 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions EXP royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA] CTD PMID:27496854 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions
affects binding
increases activity
ISO Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein
CTD PMID:15946813 PMID:17287592 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions
affects binding
ISO Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] CTD PMID:15946813 PMID:17287592 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein] CTD PMID:34227456 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Ins1 insulin 1 multiple interactions EXP royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein] CTD PMID:18981581 NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
decreases expression
ISO
EXP
royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA]
royal jelly results in decreased expression of MYC mRNA
royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]
CTD PMID:27496854 PMID:35099105 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein] CTD PMID:34227456 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] CTD PMID:30896085 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein] CTD PMID:34227456 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Tff1 trefoil factor 1 increases expression ISO royal jelly results in increased expression of TFF1 mRNA CTD PMID:15946813 NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] CTD PMID:30896085 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Vegfa vascular endothelial growth factor A increases expression ISO
EXP
royal jelly results in increased expression of VEGFA mRNA CTD PMID:15946813 PMID:17287592 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19831
    role 19807
      application 19650
        pharmaceutical 19491
          drug 19491
            nutraceutical 13252
              L-lysine 54
                Arg-Lys-Cys-Gly 0
                Asn-Lys-His-His 0
                Asp-Lys-Ile 0
                Glu-Glu-Lys 0
                Glu-Lys 0
                Glu-Lys-Trp-Ala 0
                Ile-Lys 0
                L-Lys-D-Asp 0
                L-Lys-D-Glu 0
                L-lysine derivative + 1
                L-lysine hydrochloride 0
                L-lysine residue + 21
                L-lysyl group + 0
                L-lysyl-L-amino acid 0
                Leu-Lys 0
                Leu-Lys-Asp 0
                Lys-Asp 0
                Lys-Asp-Tyr 0
                Lys-Gln 0
                Lys-Glu-Glu 0
                Lys-Glu-Thr 0
                Lys-Gly 0
                Lys-Leu-Ser 0
                Lys-Lys-Leu 0
                Lys-Met-Met-Met 0
                Lys-Phe 0
                Lys-Ser-Trp 0
                Lys-Thr 0
                Lys-Thr-Pro-Pro 0
                Lys-Thr-Trp-Tyr 0
                Lys-Tyr 0
                Lys-Tyr-Glu 0
                Lys-Val 0
                N(2)-L-lysino group + 0
                N(6)-L-lysino group 0
                Phe-Lys 0
                Ser-Asp-Lys 0
                Ser-Asp-Lys-Pro + 16
                Ser-Lys 0
                Ser-Trp-Lys 0
                Thr-Lys 0
                desmosine + 0
                p-Ts-L-Lys-Me 0
                royal jelly 20
Path 2
Term Annotations click to browse term
  CHEBI ontology 19831
    subatomic particle 19829
      composite particle 19829
        hadron 19829
          baryon 19829
            nucleon 19829
              atomic nucleus 19829
                atom 19829
                  main group element atom 19779
                    main group molecular entity 19779
                      s-block molecular entity 19617
                        hydrogen molecular entity 19604
                          hydrides 19102
                            inorganic hydride 18114
                              pnictogen hydride 18103
                                nitrogen hydride 18010
                                  azane 17819
                                    ammonia 17818
                                      organic amino compound 17818
                                        primary amino compound 9308
                                          primary amine 6325
                                            primary aliphatic amine 189
                                              butan-1-amine 55
                                                4-aminobutyl group 54
                                                  lysine 54
                                                    L-lysine 54
                                                      Arg-Lys-Cys-Gly 0
                                                      Asn-Lys-His-His 0
                                                      Asp-Lys-Ile 0
                                                      Glu-Glu-Lys 0
                                                      Glu-Lys 0
                                                      Glu-Lys-Trp-Ala 0
                                                      Ile-Lys 0
                                                      L-Lys-D-Asp 0
                                                      L-Lys-D-Glu 0
                                                      L-lysine derivative + 1
                                                      L-lysine hydrochloride 0
                                                      L-lysine residue + 21
                                                      L-lysyl group + 0
                                                      L-lysyl-L-amino acid 0
                                                      Leu-Lys 0
                                                      Leu-Lys-Asp 0
                                                      Lys-Asp 0
                                                      Lys-Asp-Tyr 0
                                                      Lys-Gln 0
                                                      Lys-Glu-Glu 0
                                                      Lys-Glu-Thr 0
                                                      Lys-Gly 0
                                                      Lys-Leu-Ser 0
                                                      Lys-Lys-Leu 0
                                                      Lys-Met-Met-Met 0
                                                      Lys-Phe 0
                                                      Lys-Ser-Trp 0
                                                      Lys-Thr 0
                                                      Lys-Thr-Pro-Pro 0
                                                      Lys-Thr-Trp-Tyr 0
                                                      Lys-Tyr 0
                                                      Lys-Tyr-Glu 0
                                                      Lys-Val 0
                                                      N(2)-L-lysino group + 0
                                                      N(6)-L-lysino group 0
                                                      Phe-Lys 0
                                                      Ser-Asp-Lys 0
                                                      Ser-Asp-Lys-Pro + 16
                                                      Ser-Lys 0
                                                      Ser-Trp-Lys 0
                                                      Thr-Lys 0
                                                      desmosine + 0
                                                      p-Ts-L-Lys-Me 0
                                                      royal jelly 20
paths to the root